CHAT and ischemia: Counts revealed only few ChAT+ cells in the ischemia (2.2±0.6 cells/mm; p<0.001) and the ranibizumab groups (1.9±0.6 cells/mm; p<0.001), when compared to controls (8.9±1.3 cells/mm; Fig 4B).